Researchers at Mayo Clinic, and the Center for Individualized Medicine, have recently been utilizing genomic sequencing to help develop personalized care treatments for men with castration-resistant prostate cancer, a progressive and incurable stage of prostate cancer that no longer responds to hormone therapies that stop or slow testosterone production.
“Men with castration-resistant prostate cancer have abysmal survival rates, typically living an average of two years once hormone therapies fail,” says Manish Kohli, M.D., a Mayo Clinic oncologist and principal investigator of the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study.
The FDA has recently approved several new therapies for use in treating castration-resistant prostate cancer. Many questions remain, however, over which medications to use in individual cases. Researchers and doctors utilize exome sequencing and RNA profiling in the PROMOTE study, to identify biomarkers within prostate cancers that can help identify the optimal drug for each individual patient.